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BACKGROUND
Cystic fibrosis is a life-limiting disease that is caused by defective or deficient cystic 
fibrosis transmembrane conductance regulator (CFTR) protein activity. Phe508del is 
the most common CFTR mutation.
METHODS
We conducted two phase 3, randomized, double-blind, placebo-controlled studies 
that were designed to assess the effects of lumacaftor (VX-809), a CFTR corrector, 
in combination with ivacaftor (VX-770), a CFTR potentiator, in patients 12 years 
of age or older who had cystic fibrosis and were homozygous for the Phe508del 
CFTR mutation. In both studies, patients were randomly assigned to receive either 
lumacaftor (600 mg once daily or 400 mg every 12 hours) in combination with 
ivacaftor (250 mg every 12 hours) or matched placebo for 24 weeks. The primary 
end point was the absolute change from baseline in the percentage of predicted 
forced expiratory volume in 1 second (FEV1) at week 24.
RESULTS
A total of 1108 patients underwent randomization and received study drug. The mean 
baseline FEV1 was 61% of the predicted value. In both studies, there were signifi-
cant improvements in the primary end point in both lumacaftor–ivacaftor dose 
groups; the difference between active treatment and placebo with respect to the 
mean absolute improvement in the percentage of predicted FEV1 ranged from 2.6 to 
4.0 percentage points (P<0.001), which corresponded to a mean relative treatment 
difference of 4.3 to 6.7% (P<0.001). Pooled analyses showed that the rate of pul-
monary exacerbations was 30 to 39% lower in the lumacaftor–ivacaftor groups 
than in the placebo group; the rate of events leading to hospitalization or the use 
of intravenous antibiotics was lower in the lumacaftor–ivacaftor groups as well. 
The incidence of adverse events was generally similar in the lumacaftor–ivacaftor 
and placebo groups. The rate of discontinuation due to an adverse event was 4.2% 
among patients who received lumacaftor–ivacaftor versus 1.6% among those who 
received placebo.
CONCLUSIONS
These data show that lumacaftor in combination with ivacaftor provided a benefit 
for patients with cystic fibrosis homozygous for the Phe508del CFTR mutation. 
(Funded by Vertex Pharmaceuticals and others; TRAFFIC and TRANSPORT 
ClinicalTrials.gov numbers, NCT01807923 and NCT01807949.)
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Cystic fibrosis is a genetic disease that is associated with high rates of pre-mature death.1-4 It is a multisystem disease 
that is characterized by pancreatic insufficiency 
and chronic airway infections associated with 
loss of lung function, repeated pulmonary exacer-
bations, and, ultimately, respiratory failure.5
Cystic fibrosis is caused by gene mutations 
that result in deficient or dysfunctional cystic 
fibrosis transmembrane conductance regulator 
(CFTR) protein, an anion channel that is normal-
ly present in the epithelial membrane. Phe508del 
(c.1521_1523delCTT; formerly F508del) is the 
most common CFTR mutation; approximately 
45% of patients with cystic fibrosis are homozy-
gous for this allele.1 Cystic fibrosis is a progres-
sive disease; despite advances in therapies de-
signed to address the symptoms of the disease, 
the median predicted survival among patients 
who are homozygous for Phe508del in the United 
States is 37 years.6 The Phe508del CFTR mutation 
causes a processing defect that severely reduces 
protein levels at the epithelial membrane; for the 
few channels that reach the cell surface, the mu-
tation also disrupts channel opening; together, 
these effects lead to minimal CFTR chloride 
transport activity.7-10 One approach to treating 
cystic fibrosis is to address the underlying cause 
of the disease by targeting the CFTR protein 
dysfunction. Restoring chloride transport to 
p.Phe508del CFTR (formerly F508del CFTR) is 
therefore thought to require at least two steps: 
correction of cellular misprocessing to increase 
the amount of functional mutated CFTR and 
potentiation to further increase channel opening.
Lumacaftor is an investigational CFTR cor-
rector that has been shown in vitro to correct 
p.Phe508del CFTR misprocessing and increase 
the amount of cell surface–localized protein.11 
Ivacaftor is an approved CFTR potentiator that 
increases the open probability of CFTR channels 
(i.e., the fraction of time that the channels are 
open) in vitro and improves clinical outcomes in 
patients 6 years of age or older who have cystic 
fibrosis and at least one copy of most class III 
(gating) mutations.12-17 In vitro studies have shown 
that ivacaftor also potentiates surface-localized 
p.Phe508del CFTR,18 and the combination of 
lumacaftor with ivacaftor has been associated 
with a greater increase in chloride transport 
than has either agent alone.11
Although neither ivacaftor nor lumacaftor 
monotherapy has been shown to have meaningful 
clinical efficacy in patients who are homozygous 
for the Phe508del CFTR mutation,19,20 a phase 2 
study suggested that the combination of luma-
caftor and ivacaftor increased CFTR activity to a 
degree that may be sufficient to improve clinical 
outcomes in these patients.21 Therefore, two phase 
3 trials (TRAFFIC and TRANSPORT) were con-
ducted to evaluate the efficacy and safety of two 
different doses of lumacaftor in combination with 
ivacaftor in patients with cystic fibrosis who were 
homozygous for the Phe508del CFTR mutation.
Me thods
Study Design and Oversight
The TRAFFIC and TRANSPORT trials were two 
phase 3, multinational, randomized, double-
blind, placebo-controlled, parallel-group studies 
in which lumacaftor (VX-809, Vertex Pharmaceu-
ticals) was orally administered in combination 
with ivacaftor (VX-770, Vertex Pharmaceuticals) 
for 24 weeks; the studies were conducted from 
April 2013 through April 2014. The study design 
and methods of data analysis were identical for 
the two studies, with the exception of the inclu-
sion of ambulatory electrocardiography (TRAFFIC 
only) and adolescent pharmacokinetic assess-
ments (TRANSPORT only) for a subgroup of pa-
tients. The studies were designed to evaluate the 
efficacy of lumacaftor–ivacaftor in patients with 
cystic fibrosis who were homozygous for the 
Phe508del CFTR mutation; the evaluation of safety 
was a secondary objective. The protocols (avail-
able with the full text of this article at NEJM.org) 
were reviewed and approved by an ethics com-
mittee at each of the 187 participating centers; 
all patients provided written informed consent.
Patients were randomly assigned (in a 1:1:1 
ratio) to one of three study groups (Fig. S1 in the 
Supplementary Appendix, available at NEJM.org): 
600 mg of lumacaftor once daily in combination 
with 250 mg of ivacaftor every 12 hours (LUM 
[600 mg/day]–IVA), 400 mg of lumacaftor every 
12 hours in combination with 250 mg of ivacaftor 
every 12 hours (LUM [400 mg every 12 hr]–IVA), 
or lumacaftor-matched placebo every 12 hours 
in combination with ivacaftor-matched placebo 
every 12 hours. All regimens were given for 24 
weeks. Randomization was stratified according 
to age (<18 years vs. ≥18 years), sex, and pulmo-
nary function (percentage of predicted forced 
expiratory volume in 1 second [FEV1] at screen-
ing, <70 vs. ≥70).
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The sponsor of the studies (Vertex Pharma-
ceuticals) designed the protocol in collaboration 
with the authors. Site investigators collected the 
data, which were analyzed by the sponsor. All 
the authors had full access to the study data 
after the study periods were complete and the 
data were unblinded. The authors vouch for the 
accuracy and completeness of the data and for 
the fidelity of this report to the study protocols, 
which are available at NEJM.org.
Study Participants
Eligibility criteria included a confirmed diagno-
sis of cystic fibrosis, homozygosity for the Phe-
508del CFTR mutation, an age of 12 years or 
older, a percentage of predicted FEV1 at the time 
of screening that was 40 to 90% of the predicted 
normal values,22,23 and stable cystic fibrosis dis-
ease. Between the screening and baseline visits 
(≤4 weeks), fluctuation in FEV1 occurred in some 
cases and was documented; 81 patients had an 
FEV1 that fell to below 40% of the predicted 
value at baseline. Patients continued to take 
their prestudy medications.
Study Assessments
All assessments were prespecified in the study 
protocols and statistical analysis plans unless 
otherwise noted. The primary end point was the 
absolute change from baseline at week 24 in the 
percentage of predicted FEV1, calculated by aver-
aging the mean absolute change at week 16 and 
the mean absolute change at week 24; this ap-
proach was used because we anticipated that it 
would reduce variability, as compared with using 
the point estimate at week 24 alone. Key second-
ary end points included the relative change from 
baseline in the percentage of predicted FEV1 
(calculated by averaging the mean values for 
weeks 16 and 24), the absolute change from 
baseline at week 24 in body-mass index (BMI), 
the absolute change from baseline at week 24 in 
the patient-reported Cystic Fibrosis Question-
naire–Revised (CFQ-R) respiratory domain score 
(scores range from 0 to 100, with higher scores 
indicating a higher patient-reported quality of 
life with regard to respiratory status),24 the per-
centage of patients with a relative increase from 
baseline of 5% or higher in the percentage of 
predicted FEV1 (calculated by averaging the 
mean values for weeks 16 and 24), and the num-
ber of pulmonary exacerbations through week 
24. The time to the first pulmonary exacerbation 
was assessed, as was the absolute change in 
body weight. The safety of the study regimens 
was also evaluated. Subgroup analyses and ad-
ditional assessments of exacerbation, including 
assessments of the numbers of patients requir-
ing hospitalization and those requiring treat-
ment with intravenous antibiotics, were also 
performed.
Statistical Analyses
All patients who underwent randomization and 
received at least one dose of study drug were 
included in the efficacy analysis, in which pa-
tients were analyzed as part of the study group 
to which they were randomly assigned (full 
analysis set). In the primary analysis, we evalu-
ated the treatment difference in the percentage 
of predicted FEV1 at week 24, which was as-
sessed as the difference between the treatment 
groups and the placebo group in the primary 
end point.
The safety set included all patients who re-
ceived any amount of study drug; data were ana-
lyzed according to the patients’ actual study 
group (regardless of the group to which they had 
been randomly assigned). The reported adverse 
events are those that either developed or in-
creased in severity at or after the time patients 
received the initial dose of study drug, up to 28 
days after receipt of the last dose. Additional 
details regarding the statistical analysis, includ-
ing the hierarchical testing procedure for the 
multiple end points and the criteria for the as-
sessment of statistical significance, are provided 
in the Supplementary Appendix.
R esult s
Participants
Of the 1122 patients who underwent randomiza-
tion (559 in the TRAFFIC study and 563 in the 
TRANSPORT study), 1108 received at least one 
dose of study drug or placebo (Fig. S2 in the 
Supplementary Appendix). The baseline demo-
graphic and other characteristics were well bal-
anced across study groups (Table 1, and Table S1 
in the Supplementary Appendix). The mean 
baseline FEV1 was 61% of the predicted value. At 
baseline, a high percentage of patients reported 
maintenance use of multiple pulmonary, nutri-
tional, and other cystic fibrosis therapies. The 
majority of patients completed their assigned 
study regimens: 348 patients in the LUM (600 
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mg/day)–IVA group (94.6%), 344 patients in the 
LUM (400 mg every 12 hr)–IVA group (93.2%), 
and 362 patients in the placebo group (97.6%).
Clinical Efficacy
In both studies, FEV1 improvements were ob-
served as early as day 15 and were sustained 
through 24 weeks in both lumacaftor–ivacaftor 
dose groups (Fig. 1A, and Fig. S3 and S4 in the 
Supplementary Appendix). The difference be-
tween lumacaftor–ivacaftor and placebo with 
respect to the mean absolute change in the per-
centage of predicted FEV1 from baseline at week 
24 was significant in all dose groups and ranged 
from 2.6 to 4.0 percentage points (P<0.001 for 
all comparisons) (Table 2). The difference be-
tween lumacaftor–ivacaftor and placebo with 
respect to the mean relative change in FEV1 was 
also significant and ranged from 4.3 to 6.7% 
(P<0.001 for all groups) (Table 2). In each study, 
the percentage of patients who had a relative 
improvement in the percentage of predicted FEV1 
of 5% or higher was greater in the lumacaftor–
ivacaftor groups than in the placebo group 
(P<0.001 to P = 0.002 for the odds ratio) but was 
not significant in the testing hierarchy (Table 2, 
and Table S2 in the Supplementary Appendix). In 
the pooled analysis, approximately twice as 
many patients in the lumacaftor–ivacaftor 
groups as in the placebo group had a relative 
improvement in the percentage of predicted FEV1 
of 5% or higher (39 to 46% vs. 22%) and 10% or 
higher (24 to 27% vs. 13%) (Table 2, and Table 
S2 and Fig. S5 in the Supplementary Appendix). 
The mean absolute change in the percentage of 
predicted FEV1 was also assessed in a variety of 
subgroups (e.g., subgroups defined according to 
various baseline characteristics and concomitant 
Characteristic
Placebo 
(N = 371)
LUM (600 mg/day)–IVA 
(N = 368)
LUM (400 mg 
every 12 hr)–IVA 
(N = 369)
Female sex — no. (%) 181 (48.8) 182 (49.5) 182 (49.3)
Mean age (range) — yr 25.4 (12–64) 24.5 (12–54) 25.3 (12–57)
Age group — no. (%)
12 to <18 yr 96 (25.9) 96 (26.1) 98 (26.6)
≥18 yr 275 (74.1) 272 (73.9) 271 (73.4)
Percentage of predicted FEV1 at baseline
Mean (range) 60.4 (33.9–99.8) 60.8 (31.1–92.3) 60.5 (31.3–96.5)
Subgroup — no. (%)
<40 28 (7.5) 24 (6.5) 29 (7.9)
≥40 to <70 238 (64.2) 241 (65.5) 233 (63.1)
≥70 to ≤90 97 (26.1) 98 (26.6) 100 (27.1)
>90 3 (0.8) 3 (0.8) 3 (0.8)
Mean BMI (range)† 21.0 (14.1–32.2) 21.0 (14.2–35.1) 21.5 (14.6–31.4)
Maintenance use of pulmonary or respiratory cystic fibrosis 
therapy at baseline — no. (%)
Bronchodilators 342 (92.2) 342 (92.9) 344 (93.2)
Dornase alfa 281 (75.7) 289 (78.5) 273 (74.0)
Inhaled antibiotics 258 (69.5) 232 (63.0) 225 (61.0)
Azithromycin 233 (62.8) 233 (63.3) 215 (58.3)
Inhaled hypertonic saline 220 (59.3) 197 (53.5) 227 (61.5)
Inhaled glucocorticoids 220 (59.3) 213 (57.9) 212 (57.5)
*  The LUM (600 mg/day)–IVA group received 600 mg of lumacaftor (LUM) once daily in combination with 250 mg of ivacaftor (IVA) every 12 hours; 
the LUM (400 mg every 12 hr)–IVA group received 400 mg of lumacaftor every 12 hours in combination with 250 mg of ivacaftor every 12 hours. 
FEV1 denotes forced expiratory volume in 1 second.
†  The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
Table 1. Baseline Characteristics and Demographic Data.*
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medications); the improvement in the percentage 
of predicted FEV1 in the lumacaftor–ivacaftor 
groups versus the placebo group was consistent 
across all subgroups (Fig. 1B, and Fig. S6 in the 
Supplementary Appendix). Additional details are 
provided in the Supplementary Appendix.
Clinically meaningful reductions in the rates 
of protocol-defined pulmonary exacerbations 
were seen in both lumacaftor–ivacaftor dose 
groups. The rate ratio (lumacaftor–ivacaftor vs. 
placebo) ranged from 0.57 to 0.72 (P<0.001 to 
P = 0.05; none of the rate ratios were considered 
significant in the testing hierarchy) (Table 2, 
and Table S2 in the Supplementary Appendix). In 
the pooled analysis, the rate of exacerbations 
was significantly lower in both lumacaftor–iva-
caftor dose groups than in the placebo group: 
30% lower in the LUM (600 mg/day)–IVA group 
and 39% lower in the LUM (400 mg every 12 hr)–
IVA group (P = 0.001 and P<0.001, respectively) 
(Table 2, and Table S2 in the Supplementary Ap-
pendix). Through week 24, the proportion of 
patients who remained free from exacerbations 
in the pooled analysis was significantly higher 
in both lumacaftor–ivacaftor groups than in the 
placebo group, and the risk of having an exacer-
bation was significantly lower in the luma-
caftor–ivacaftor groups (Fig. 2A and Table 2). 
Additional analyses revealed significant reduc-
tions with lumacaftor–ivacaftor therapy in the 
number of exacerbations leading to hospitaliza-
tions and those necessitating the administration 
of intravenous antibiotics (Fig. 2B).
Over the course of the 24-week period, the 
mean BMI (the weight in kilograms divided by 
the square of the height in meters) increased 
steadily in both lumacaftor–ivacaftor dose 
groups (Fig. S7 in the Supplementary Appendix). 
Figure 1. Absolute Changes from Baseline in the Percent-
age of Predicted Forced Expiratory Volume in 1 Second 
(FEV1) According to Study Group.
The LUM (600 mg/day)–IVA group received 600 mg of 
lumacaftor (LUM) once daily in combination with 250 mg 
of ivacaftor (IVA) every 12 hours; the LUM (400 mg 
 every 12 hr)–IVA group received 400 mg of lumacaftor 
every 12 hours in combination with 250 mg of ivacaftor 
every 12 hours. Panel A shows the mean absolute change 
in the percentage of predicted FEV1 over time in each 
study group; the difference between each active-treat-
ment group and the placebo group at each time point 
was significant (P<0.025). Panel B shows subgroup 
analyses of the differences between the active treat-
ment and placebo in the absolute change from baseline 
in the percentage of predicted FEV1 at week 24. Data in 
both panels are least-squares means; I bars indicate 
95% confidence intervals. The results represent pooled 
data from the TRAFFIC and TRANSPORT studies.
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In the analysis of the individual trials, the differ-
ence between lumacaftor–ivacaftor and placebo 
with respect to the absolute change in BMI was 
significant for both dose groups in the TRANS-
PORT study but for neither dose group in the 
TRAFFIC study (Table 2). In the pooled analysis 
at week 24, the treatment difference versus pla-
cebo with respect to the absolute change in BMI 
was 0.24 to 0.28 (P<0.001) (Table 2, and Table S2 
and Fig. S7 in the Supplementary Appendix); this 
represents an improvement of approximately 1% 
with lumacaftor–ivacaftor. Across the luma-
caftor–ivacaftor dose groups in TRAFFIC and 
TRANSPORT, the least-squares mean change 
from baseline in body weight at week 24 ranged 
from 1.23 to 1.57 kg.
The CFQ-R is a cystic fibrosis–specific instru-
ment that is designed to evaluate patient-report-
ed assessments of various health-related mea-
sures. In both lumacaftor–ivacaftor dose groups, 
there were improvements in the within-group 
CFQ-R respiratory domain score; the treatment 
difference versus placebo was nominally signifi-
cant (on the basis of the testing hierarchy) in the 
analysis of the individual trials only for the LUM 
(600 mg/day)–IVA group in the TRAFFIC study; 
the treatment difference reached significance in 
the LUM (600 mg/day)–IVA group in the pooled 
analysis (Table 2, and Fig. S8 in the Supplemen-
tary Appendix).
Safety
Overall, the proportion of patients reporting 
adverse events was similar across the luma-
caftor–ivacaftor groups and the placebo group 
(Table 3). Pooled across the studies, serious ad-
verse events were reported in 28.6% of the pa-
tients in the placebo group and in 17.3 to 22.8% 
of the patients in the lumacaftor–ivacaftor 
groups. In all the groups, infective pulmonary 
exacerbation was the most common serious ad-
verse event (occurring in 24.1% of the patients in 
the placebo group and in 13.0% of those in the 
pooled lumacaftor–ivacaftor groups). The pro-
portion of patients who discontinued the study 
regimen because of an adverse event was higher 
in the lumacaftor–ivacaftor groups than in the 
placebo group (4.2% [31 of 738 patients] vs. 
1.6% [6 of 370 patients]). Among the patients 
receiving lumacaftor–ivacaftor, the adverse 
events that led to discontinuation of the study 
regimen in two or more patients were elevation 
of the creatine kinase level (4 patients), hemop-
tysis (3), bronchospasm (2), dyspnea (2), pulmo-
nary exacerbation (2), and rash (2). No deaths 
were reported.
The adverse events reported more frequently 
in the lumacaftor–ivacaftor groups were gener-
ally respiratory in nature. The majority were of 
mild-to-moderate severity and included dyspnea 
and chest tightness (Table 3, and Table S3 in the 
Supplementary Appendix). Two patients in the 
placebo group (one with dyspnea and one with 
chest discomfort) and four patients in the LUM 
(600 mg/day)–IVA group (two with dyspnea and 
two with bronchospasm) had adverse events of 
respiratory symptoms or reactive airways that 
were severe. In patients who had respiratory-
symptom adverse events within 1 to 2 days after 
the initiation of therapy and who did not discon-
tinue the study regimen, the events generally 
resolved within the first 2 to 3 weeks of therapy. 
Beyond the first week of therapy, the incidence 
of respiratory events was similar in the luma-
caftor–ivacaftor and placebo groups. In addi-
tion, the pattern of adverse events according to 
the severity of lung disease at baseline was 
generally similar across the groups.
Elevations in levels of alanine or aspartate 
aminotransferase to more than 3 times the up-
per limit of the normal range were observed in 
5.1% of the patients in the placebo group and in 
5.2% of those in the lumacaftor–ivacaftor groups 
(Table S4 in the Supplementary Appendix). Seri-
ous adverse events related to abnormal liver 
function were not observed in the placebo group 
and were reported for seven patients in the lu-
macaftor–ivacaftor groups. After discontinua-
tion or interruption of lumacaftor–ivacaftor 
therapy, liver function in all patients improved 
substantially, and results of liver-function tests 
returned to baseline in the case of six patients. 
Details regarding these events, including con-
comitant elevations in bilirubin, are provided in 
the Supplementary Appendix.
Discussion
Significant improvements in the percentage of 
predicted FEV1 were seen in all four lumacaftor–
ivacaftor treatment groups in the TRAFFIC and 
TRANSPORT studies. In both dose groups in 
each study, improvements in FEV1 were seen by 
day 15 and were sustained throughout the 24-
week study period.
Lumacaftor–ivacaftor combination therapy 
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resulted in improvements in multiple clinical 
end points, and the findings were generally con-
sistent across dose groups and studies. Clini-
cally important reductions in the rate of pulmo-
nary exacerbations were also observed in 
association with lumacaftor–ivacaftor therapy. 
Through 24 weeks, the lumacaftor–ivacaftor 
groups had reductions in the rate of pulmonary 
exacerbations, with decreases in the numbers of 
events leading to hospitalization or intravenous 
antibiotic treatment. FEV1 and rates of pulmo-
nary exacerbations are strong predictors of sur-
vival and thus remain important for the evalua-
tion of new therapies for cystic fibrosis.25
Significant improvements (i.e., increases) in 
BMI were observed in the TRANSPORT study 
and in the pooled analyses but not in the TRAF-
FIC study. Across both studies, BMI continued to 
increase during the study period in both luma-
caftor–ivacaftor groups. Although the mecha-
nisms for improvement in the nutritional status 
of patients with cystic fibrosis are not fully de-
fined, the gains are hypothesized to reflect ei-
ther better caloric absorption, possibly due to 
normalized intestinal pH,17 or a reduction in 
energy expenditure resulting from amelioration 
of lung disease.17,26 Numerical increases in the 
CFQ-R respiratory domain score favoring active 
treatment were seen in both dose groups in both 
studies; however, in the pooled analysis of that 
score, the treatment difference was significant 
only in the LUM (600 mg/day)–IVA group and 
did not meet the requirement for a minimum 
clinically important difference (4 points).24 It is 
challenging to interpret these results, given the 
significant improvements in FEV1. The CFQ-R 
instrument is valuable for assessing patient-re-
ported outcomes; however, there is precedent for 
a lack of correlation with FEV1. Studies of tobra-
mycin showed no correlation between changes 
in CFQ-R and FEV1.
24 It is also worth noting that 
the CFQ-R minimum clinically important differ-
ence was established as a within-group change 
in patients who had markers of advanced dis-
ease, which complicates its application to other 
populations.24
The TRAFFIC and TRANSPORT study cohorts 
were a population with well-managed cystic fi-
brosis, as evidenced by the minimal FEV1 dete-
rioration in the placebo group and the high rates 
of the use of standard cystic fibrosis therapy. 
The magnitude of the change in FEV1 was sig-
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nificant and was in the range of the magnitudes 
of change seen in studies of other cystic fibrosis 
therapeutics.27-31 The changes due to treatment 
in the percentage of predicted FEV1 were largely 
consistent across studies, dose groups, and all 
subgroups analyzed, including subgroups de-
fined according to age, baseline FEV1 (<40 vs. 
≥40), and status with respect to Pseudomonas ae-
ruginosa infection. Improvements in FEV1 and 
BMI and reductions in exacerbations were ob-
served while patients continued to use their 
prescribed cystic fibrosis therapies; lumacaftor–
ivacaftor is therefore expected to provide a clini-
cally meaningful benefit in addition to the 
standard of care. The determination of the po-
tential for lumacaftor–ivacaftor–mediated CFTR 
modulation to modify the course of disease will 
require additional analyses and longer-term 
data.
Although the improvements in FEV1 associ-
ated with lumacaftor–ivacaftor were significant 
and consistent with in vitro11 and phase 2 sweat 
chloride and FEV1 results,
21 the effect of luma-
caftor–ivacaftor on sweat chloride and FEV1 was 
smaller than that observed in patients with the 
Gly551Asp mutation who were treated with iva-
caftor monotherapy.13,14 Whereas CFTR with the 
p.Gly551Asp mutation has a gating defect but is 
found at the cell surface, CFTR with the p.Phe-
508del mutation has multiple defects, which 
makes addressing the underlying cause of dis-
ease in patients homozygous for this mutation 
more complex. The most important of these 
defects is a substantial reduction in processing 
and transport to the cell surface, plus a reduced 
stability and channel gating of the few surface-
localized proteins. These multiple defects make 
restoring p.Phe508del CFTR activity and subse-
quent observation of a clinical benefit more 
challenging than addressing the p.Gly551Asp 
gating defect. The smaller changes in sweat 
chloride and FEV1 seen in association with luma-
caftor–ivacaftor therapy in patients homozygous 
for Phe508del, as compared with the changes 
seen in association with ivacaftor monotherapy 
in patients with Gly551Asp, was predicted in 
vitro and may be due in part to the fact that lu-
macaftor only partially rescues the p.Phe508del 
CFTR processing defect,11 which results in fewer 
p.Phe508del CFTR channels at the cell surface 
than are seen with p.Gly551Asp CFTR.
Two in vitro studies have suggested that 
treatment (for ≤48 hours) with potentiators, in-
cluding ivacaftor, may reduce the stability and 
expression of corrected p.Phe508del.32,33 Al-
though it is possible that ivacaftor affects the 
steady-state levels of corrected p.Phe508del 
CFTR in vitro, the results of the TRAFFIC and 
TRANSPORT studies, which included more than 
1100 patients, suggest that lumacaftor–ivacaftor 
provides a clinical benefit that is greater than 
that previously observed with either agent 
alone.20,21 Moreover, the clinical benefit was sus-
tained for the entire duration of the studies. 
Figure 2. Pulmonary Exacerbations.
The time to first pulmonary exacerbation and number of pulmonary exacer-
bations leading to hospitalization or treatment with intravenous antibiotics 
are shown. In Panel B, the number of pulmonary exacerbations observed 
through week 24 is expressed as a rate per patient over 48 weeks. The re-
sults represent pooled data from the TRAFFIC and TRANSPORT studies.
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Nevertheless, the differences between the results 
of treatment with lumacaftor–ivacaftor in pa-
tients with the Phe508del mutation and treat-
ment with ivacaftor in patients with the 
Gly551Asp mutation point to the need for con-
tinued development of CFTR modulators that 
will further improve on the meaningful FEV1 
benefits observed in the TRAFFIC and TRANS-
PORT studies.
Lumacaftor–ivacaftor therapy at both dosing 
regimens generally had an acceptable side-effect 
profile. The proportion of patients who discon-
tinued the study regimen for reasons related to 
an adverse event was higher among those who 
received lumacaftor–ivacaftor than among those 
who received placebo, and dyspnea and chest 
tightness were reported more frequently in the 
active-treatment groups. In a phase 2 study, 
treatment with lumacaftor monotherapy was as-
sociated with an initial increased risk of dyspnea 
or chest tightness, although these symptoms 
were uncommon after the addition of ivacaftor 
to lumacaftor.21 Elevated levels of liver enzymes 
were observed in a similar number of patients in 
the active-treatment groups and the placebo 
group; however, serious adverse events related to 
elevation of liver enzymes were reported only in 
the active-treatment group.
The TRAFFIC and TRANSPORT studies includ-
ed the same two doses of lumacaftor so that we 
could ascertain whether there was a dose response 
for the CFTR corrector. Pooled across the two 
Event
Placebo 
(N = 370)
LUM (600 mg/day)–IVA 
(N = 369)
LUM (400 mg  
every 12 hr)–IVA 
(N = 369)
number of patients (percent)
Any adverse event reported 355 (95.9) 356 (96.5) 351 (95.1)
Discontinuation of the study regimen 
because of an adverse event
6 (1.6) 14 (3.8) 17 (4.6)
At least one serious adverse event 106 (28.6) 84 (22.8) 64 (17.3)
Most common adverse events†
Infective pulmonary exacerbation of 
cystic fibrosis
182 (49.2) 145 (39.3) 132 (35.8)
Cough 148 (40.0) 121 (32.8) 104 (28.2)
Headache 58 (15.7) 58 (15.7) 58 (15.7)
Increase in sputum production 70 (18.9) 55 (14.9) 54 (14.6)
Dyspnea 29 (7.8) 55 (14.9) 48 (13.0)
Hemoptysis 50 (13.5) 52 (14.1) 50 (13.6)
Diarrhea 31 (8.4) 36 (9.8) 45 (12.2)
Nausea 28 (7.6) 29 (7.9) 46 (12.5)
Abnormal respiration (chest tight-
ness)
22 (5.9) 40 (10.8) 32 (8.7)
Nasopharyngitis 40 (10.8) 23 (6.2) 48 (13.0)
Oropharyngeal pain 30 (8.1) 44 (11.9) 24 (6.5)
Upper respiratory tract infection 20 (5.4) 24 (6.5) 37 (10.0)
Nasal congestion 44 (11.9) 33 (8.9) 24 (6.5)
Serious adverse events occurring in at least  
3 patients in any treatment group
Infective pulmonary exacerbation of 
cystic fibrosis
89 (24.1) 55 (14.9) 41 (11.1)
Hemoptysis 3 (0.8) 4 (1.1) 5 (1.4)
Distal intestinal obstruction syndrome 5 (1.4) 2 (0.5) 2 (0.5)
*  The reported adverse events are those that either developed or increased in severity at or after the time patients re-
ceived the initial dose of study drug (placebo or active agent), up to 28 days after receipt of the last dose.
†  The most common adverse events were defined as those that occurred in at least 10% of patients in any treatment group.
Table 3. Adverse Events Associated with the Study Regimens.*
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studies, the dose regimens appeared to have simi-
lar efficacy and safety profiles, with no clear dif-
ferentiation except with respect to pulmonary ex-
acerbation–related outcomes, which consistently 
favored the LUM (400 mg every 12 hr)–IVA group.
In conclusion, in the TRAFFIC and TRANSPORT 
studies, lumacaftor in combination with ivacaftor 
improved FEV1 and reduced the rate of pulmo-
nary exacerbations in patients with cystic fibro-
sis who were homozygous for the Phe508del 
CFTR mutation. Lumacaftor–ivacaftor therapy 
generally had an acceptable side-effect profile, 
with more than 93% of patients completing the 
assigned therapy regimen. These data show that 
the combination of a CFTR corrector and poten-
tiator, designed to address the underlying cause 
of cystic fibrosis by targeting CFTR, can benefit 
patients who are homozygous for the Phe508del 
CFTR mutation and represents a treatment mile-
stone for the 45% of patients with cystic fibrosis 
who are homozygous for this mutation.
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